{"component": "contracts", "props": {"contracts": [{"intro": "This Asset Purchase Agreement (the \u201cAgreement\u201d) is entered into as of this 29th day of May, 2012 (the \u201cEffective Date\u201d), by and between Glaxo Group Limited, a company incorporated under the laws of England and Wales with offices at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN under company number 00305979 (\u201cGSK\u201d) and Welichem Biotech Inc., a company incorporated under the laws of British Columbia with offices at Suite 316, 4475 Wayburne Drive, Burnaby, British Columbia, V5G 3L1, Canada (\u201cWelichem\u201d). GSK and Welichem may be referred to herein separately as a \u201cParty\u201d or together as the \u201cParties.\u201d", "id": "eWRnlVTY37Z", "source_url": "https://www.sec.gov/Archives/edgar/data/1753483/000095012319002639/filename18.htm", "category_name": "Asset Purchase Agreement", "company_name": "Dermavant Sciences LTD", "created": "March 11th, 2019", "published": true, "pretty": null, "uri": "/contracts/eWRnlVTY37Z", "title": "ASSET PURCHASE AGREEMENT", "group_id": "eWRnlVTY37Z", "group_samples": [{"label": "Asset Purchase Agreement (Dermavant Sciences LTD)", "uri": "/contracts/eWRnlVTY37Z", "published": true}], "group_size": 1, "tags": [{"name": "Asset Purchase Agreement", "type": "category", "uri": "/contracts/tagged/asset-purchase-agreement"}, {"name": "Dermavant Sciences LTD", "type": "company", "uri": "/company/1753483/dermavant-sciences-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This LICENSE AGREEMENT (\u201cAgreement\u201d) is made as of December 16, 2016 (\u201cEffective Date\u201d), by and between Portola Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, having its principal place of business at 270 East Grand Avenue, Suite 22, South San Francisco, CA 94080, USA (\u201cPortola\u201d), and Dermavant Sciences GmbH, a corporation organized and existing under the laws of Switzerland, having its principal place of business at c/o Vischer AG, Aeschenvotstadt 4, CH-4010 Basel, Switzerland (\u201cDermavant\u201d). Dermavant and Portola are referred to individually as a \u201cParty\u201d and collectively as the \u201cParties.\u201d", "id": "euhI19NmGhs", "source_url": "https://www.sec.gov/Archives/edgar/data/1753483/000095012319002639/filename5.htm", "category_name": "License Agreement", "company_name": "Dermavant Sciences LTD", "created": "March 11th, 2019", "published": true, "pretty": null, "uri": "/contracts/euhI19NmGhs", "title": "LICENSE AGREEMENT", "group_id": "euhI19NmGhs", "group_samples": [{"label": "License Agreement (Dermavant Sciences LTD)", "uri": "/contracts/euhI19NmGhs", "published": true}], "group_size": 1, "tags": [{"name": "License Agreement", "type": "category", "uri": "/contracts/tagged/license-agreement"}, {"name": "Dermavant Sciences LTD", "type": "company", "uri": "/company/1753483/dermavant-sciences-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "Your employment with Dermavant Sciences, Inc. has been terminated effective February 8, 2019 (\u201cSeparation Date\u201d). This Separation Agreement and General Release (this \u201cAgreement\u201d) sets forth the terms and conditions under which Dermavant Sciences, Inc. is offering you additional pay and benefits in exchange for you making and honoring certain commitments, including agreeing not to pursue legal action against the Company as described in Sections 7 and 8.", "id": "evZ2vazVn4V", "source_url": "https://www.sec.gov/Archives/edgar/data/1753483/000095012319002639/filename20.htm", "category_name": "Separation Agreement and General Release", "company_name": "Dermavant Sciences LTD", "created": "March 11th, 2019", "published": true, "pretty": null, "uri": "/contracts/evZ2vazVn4V", "title": "RE: Separation Agreement and General Release", "group_id": "evZ2vazVn4V", "group_samples": [{"label": "Separation Agreement and General Release (Dermavant Sciences LTD)", "uri": "/contracts/evZ2vazVn4V", "published": true}], "group_size": 1, "tags": [{"name": "Separation Agreement and General Release", "type": "category", "uri": "/contracts/tagged/separation-agreement-and-general-release"}, {"name": "Dermavant Sciences LTD", "type": "company", "uri": "/company/1753483/dermavant-sciences-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "", "id": "fHL7JgTUSGo", "source_url": "https://www.sec.gov/Archives/edgar/data/1753483/000095012319002639/filename8.htm", "category_name": "License Agreement", "company_name": "Dermavant Sciences LTD", "created": "March 11th, 2019", "published": true, "pretty": null, "uri": "/contracts/fHL7JgTUSGo", "title": "LICENSE AGREEMENT", "group_id": "fHL7JgTUSGo", "group_samples": [{"label": "License Agreement (Dermavant Sciences LTD)", "uri": "/contracts/fHL7JgTUSGo", "published": true}], "group_size": 1, "tags": [{"name": "License Agreement", "type": "category", "uri": "/contracts/tagged/license-agreement"}, {"name": "Dermavant Sciences LTD", "type": "company", "uri": "/company/1753483/dermavant-sciences-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This Asset Purchase Agreement (this \u201cAgreement\u201d) is made and dated as of July 10, 2018, by and among Glaxo Group Limited, a company incorporated under the laws of England and Wales (\u201cGGL\u201d), GlaxoSmithKline Intellectual Property Development Ltd., a company incorporated under the laws of England and Wales (\u201cGIPD,\u201d and together with GGL, \u201cSeller Parties\u201d) and Dermavant Sciences GmbH, a company incorporated under the laws of Switzerland (\u201cBuyer\u201d). Seller Parties and Buyer may each be referred to herein individually as a \u201cParty\u201d and collectively as the \u201cParties.\u201d", "id": "gbVZ3OOp7vb", "source_url": "https://www.sec.gov/Archives/edgar/data/1753483/000095012319002639/filename2.htm", "category_name": "Asset Purchase Agreement", "company_name": "Dermavant Sciences LTD", "created": "March 11th, 2019", "published": true, "pretty": null, "uri": "/contracts/gbVZ3OOp7vb", "title": "ASSET PURCHASE AGREEMENT by and among GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD., GLAXO GROUP LIMITED, AND DERMAVANT SCIENCES GMBH July 10, 2018", "group_id": "gbVZ3OOp7vb", "group_samples": [{"label": "Asset Purchase Agreement (Dermavant Sciences LTD)", "uri": "/contracts/gbVZ3OOp7vb", "published": true}], "group_size": 1, "tags": [{"name": "Asset Purchase Agreement", "type": "category", "uri": "/contracts/tagged/asset-purchase-agreement"}, {"name": "Dermavant Sciences LTD", "type": "company", "uri": "/company/1753483/dermavant-sciences-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "This Employment Agreement (this \u201cAgreement\u201d) is entered into as of March 18, 2019, by and between Cyril Allouche (the \u201cExecutive\u201d) and Dermavant Sciences, Inc. (the \u201cCompany\u201d).", "id": "hdA67ZGiEAf", "source_url": "https://www.sec.gov/Archives/edgar/data/1753483/000095012319002953/filename4.htm", "category_name": "Employment Agreement", "company_name": "Dermavant Sciences LTD", "created": "March 29th, 2019", "published": true, "pretty": null, "uri": "/contracts/hdA67ZGiEAf", "title": "DERMAVANT SCIENCES, INC. EMPLOYMENT AGREEMENT", "group_id": "hdA67ZGiEAf", "group_samples": [{"label": "Employment Agreement (Dermavant Sciences LTD)", "uri": "/contracts/hdA67ZGiEAf", "published": true}], "group_size": 1, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "Dermavant Sciences LTD", "type": "company", "uri": "/company/1753483/dermavant-sciences-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This Retention Agreement (this \u201cAgreement\u201d) is being provided to you in furtherance of our prior discussions regarding your transition from the position of Chief Medical Officer (\u201cCMO\u201d) of Dermavant Sciences, Inc. (\u201c Dermavant\u201d or the \u201cCompany\u201d). This Agreement reflects terms discussed with you following the Company\u2019s delivery of the Agreement to you on September 4, 2018. Consistent with such discussions, this Agreement sets forth the terms for the continuation of your employment with the Company for a transitional period extending through December 3, 2018, or such earlier date as may be determined by the Company in its sole discretion as provided for herein (such date being referred to as the \u201cTermination Date\u201d). Further, this Agreement sets forth the additional pay and benefits the Company is offering you in connection with your continuation of employment through the Termination Date on the terms and conditions set forth herein, and in consideration for making and honoring certain co", "id": "hvip36Vxxy", "source_url": "https://www.sec.gov/Archives/edgar/data/1753483/000095012318012452/filename10.htm", "category_name": "Retention Agreement", "company_name": "Dermavant Sciences LTD", "created": "December 20th, 2018", "published": true, "pretty": null, "uri": "/contracts/hvip36Vxxy", "title": "RE: Retention Agreement", "group_id": "hvip36Vxxy", "group_samples": [{"label": "Retention Agreement (Dermavant Sciences LTD)", "uri": "/contracts/hvip36Vxxy", "published": true}], "group_size": 1, "tags": [{"name": "Retention Agreement", "type": "category", "uri": "/contracts/tagged/retention-agreement"}, {"name": "Dermavant Sciences LTD", "type": "company", "uri": "/company/1753483/dermavant-sciences-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This LICENSE AGREEMENT (\u201cAgreement\u201d) is made as of December 16, 2016 (\u201cEffective Date\u201d), by and between Portola Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, having its principal place of business at 270 East Grand Avenue, Suite 22, South San Francisco, CA 94080, USA (\u201cPortola\u201d), and Dermavant Sciences GmbH, a corporation organized and existing under the laws of Switzerland, having its principal place of business at c/o Vischer AG, Aeschenvotstadt 4, CH-4010 Basel, Switzerland (\u201cDermavant\u201d). Dermavant and Portola are referred to individually as a \u201cParty\u201d and collectively as the \u201cParties.\u201d", "id": "iVEA4FGlzzY", "source_url": "https://www.sec.gov/Archives/edgar/data/1753483/000119312519157086/d625659dex103.htm", "category_name": "License Agreement", "company_name": "Dermavant Sciences LTD", "created": "May 24th, 2019", "published": true, "pretty": null, "uri": "/contracts/iVEA4FGlzzY", "title": "LICENSE AGREEMENT", "group_id": "iVEA4FGlzzY", "group_samples": [{"label": "License Agreement (Dermavant Sciences LTD)", "uri": "/contracts/iVEA4FGlzzY", "published": true}], "group_size": 1, "tags": [{"name": "License Agreement", "type": "category", "uri": "/contracts/tagged/license-agreement"}, {"name": "Dermavant Sciences LTD", "type": "company", "uri": "/company/1753483/dermavant-sciences-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "THIS AMENDMENT is made and entered into this July 7, 2017, by and between Portola Pharmaceuticals, Inc. (\u201cPortola\u201d) and Dermavant Sciences GmbH (\u201cDermavant\u201d) to amend the terms of that LICENSE AGREEMENT entered into between Portola and Dermavant dated December 16, 2016.", "id": "igdAr1MCu5E", "source_url": "https://www.sec.gov/Archives/edgar/data/1753483/000119312519157086/d625659dex104.htm", "category_name": "License Agreement", "company_name": "Dermavant Sciences LTD", "created": "May 24th, 2019", "published": true, "pretty": null, "uri": "/contracts/igdAr1MCu5E", "title": "FIRST AMENDMENT to LICENSE AGREEMENT by and between PORTOLA PHARMACEUTICALS, INC. and DERMAVANT SCIENCES GMBH", "group_id": "igdAr1MCu5E", "group_samples": [{"label": "License Agreement (Dermavant Sciences LTD)", "uri": "/contracts/igdAr1MCu5E", "published": true}], "group_size": 1, "tags": [{"name": "License Agreement", "type": "category", "uri": "/contracts/tagged/license-agreement"}, {"name": "Dermavant Sciences LTD", "type": "company", "uri": "/company/1753483/dermavant-sciences-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "THIS AMENDMENT is made and entered into this July 7, 2017, by and between Eisai Co., Ltd. (\u201cEisai\u201d) and Dermavant Sciences GmbH to amend the terms of that LICENSE AGREEMENT entered into between Eisai and Roivant Sciences Ltd. dated November 19, 2015, and subsequently assigned by Roivant Sciences Ltd. to Dermavant Sciences Ltd., and then to Dermavant Sciences GmbH (\u201cDermavant\u201d).", "id": "j4C0cMgDXza", "source_url": "https://www.sec.gov/Archives/edgar/data/1753483/000095012319002639/filename4.htm", "category_name": "License Agreement", "company_name": "Dermavant Sciences LTD", "created": "March 11th, 2019", "published": true, "pretty": null, "uri": "/contracts/j4C0cMgDXza", "title": "FIRST AMENDMENT to LICENSE AGREEMENT by and between EISAI CO., LTD. and DERMAVANT SCIENCES GMBH", "group_id": "j4C0cMgDXza", "group_samples": [{"label": "License Agreement (Dermavant Sciences LTD)", "uri": "/contracts/j4C0cMgDXza", "published": true}], "group_size": 1, "tags": [{"name": "License Agreement", "type": "category", "uri": "/contracts/tagged/license-agreement"}, {"name": "Dermavant Sciences LTD", "type": "company", "uri": "/company/1753483/dermavant-sciences-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (this \u201cAssignment and Assumption Agreement\u201d) is made and entered into as of December 17, 2018 (the \u201cEffective Date\u201d), by and between Dermavant Sciences GmbH, a company organized and existing pursuant to the laws of Switzerland having a principal place of business at Viaduktstrasse 8, Basel 4051, Switzerland (\u201cDSG\u201d) and Roivant Sciences GmbH, a company organized and existing pursuant to the laws of Switzerland having a principal place of business at Viaduktstrasse 8, Basel 4051, Switzerland (\u201cRSG\u201d).", "id": "jAU6yztBDLY", "source_url": "https://www.sec.gov/Archives/edgar/data/1753483/000095012319002639/filename12.htm", "category_name": "Assignment and Assumption Agreement", "company_name": "Dermavant Sciences LTD", "created": "March 11th, 2019", "published": true, "pretty": null, "uri": "/contracts/jAU6yztBDLY", "title": "ASSIGNMENT AND ASSUMPTION AGREEMENT", "group_id": "jAU6yztBDLY", "group_samples": [{"label": "Assignment and Assumption Agreement (Dermavant Sciences LTD)", "uri": "/contracts/jAU6yztBDLY", "published": true}], "group_size": 1, "tags": [{"name": "Assignment and Assumption Agreement", "type": "category", "uri": "/contracts/tagged/assignment-and-assumption-agreement"}, {"name": "Dermavant Sciences LTD", "type": "company", "uri": "/company/1753483/dermavant-sciences-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This LICENSE AGREEMENT (this \u201cAgreement\u201d) is made as of November 19, 2015 (the \u201cEffective Date\u201d), by and between Roivant Sciences Ltd., a Bermuda Exempted Limited Company, having its principal place of business at Clarendon House, 2 Church Street, Hamilton HM11, Bermuda (\u201cRoivant\u201d), and Eisai Co., Ltd., a corporation organized and existing under the laws of Japan, having offices at Koishikawa 4-6-10, Bunkyo-ku, Tokyo 112-8088, Japan (\u201cEisai\u201d). Roivant and Eisai are referred to in this Agreement individually as a \u201cParty\u201d and collectively as the \u201cParties.\u201d", "id": "kdRFBW6Tli8", "source_url": "https://www.sec.gov/Archives/edgar/data/1753483/000119312519157086/d625659dex101.htm", "category_name": "License Agreement", "company_name": "Dermavant Sciences LTD", "created": "May 24th, 2019", "published": true, "pretty": null, "uri": "/contracts/kdRFBW6Tli8", "title": "LICENSE AGREEMENT", "group_id": "kdRFBW6Tli8", "group_samples": [{"label": "License Agreement (Dermavant Sciences LTD)", "uri": "/contracts/kdRFBW6Tli8", "published": true}], "group_size": 1, "tags": [{"name": "License Agreement", "type": "category", "uri": "/contracts/tagged/license-agreement"}, {"name": "Dermavant Sciences LTD", "type": "company", "uri": "/company/1753483/dermavant-sciences-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "England and Wales", "type": "jurisdiction", "uri": "/contracts/tagged/england-and-wales-gb"}]}, {"intro": "THIS AMENDMENT is made and entered into this July 7, 2017, by and between Portola Pharmaceuticals, Inc. (\u201cPortola\u201d) and Dermavant Sciences GmbH (\u201cDermavant\u201d) to amend the terms of that LICENSE AGREEMENT entered into between Portola and Dermavant dated December 16, 2016.", "id": "khm4iq48Pqu", "source_url": "https://www.sec.gov/Archives/edgar/data/1753483/000095012319002639/filename6.htm", "category_name": "License Agreement", "company_name": "Dermavant Sciences LTD", "created": "March 11th, 2019", "published": true, "pretty": null, "uri": "/contracts/khm4iq48Pqu", "title": "FIRST AMENDMENT to LICENSE AGREEMENT by and between PORTOLA PHARMACEUTICALS, INC. and DERMAVANT SCIENCES GMBH", "group_id": "khm4iq48Pqu", "group_samples": [{"label": "License Agreement (Dermavant Sciences LTD)", "uri": "/contracts/khm4iq48Pqu", "published": true}], "group_size": 1, "tags": [{"name": "License Agreement", "type": "category", "uri": "/contracts/tagged/license-agreement"}, {"name": "Dermavant Sciences LTD", "type": "company", "uri": "/company/1753483/dermavant-sciences-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Asset Purchase Agreement (the \u201cAgreement\u201d) is entered into as of this 29th day of May, 2012 (the \u201cEffective Date\u201d), by and between Glaxo Group Limited, a company incorporated under the laws of England and Wales with offices at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN under company number 00305979 (\u201cGSK\u201d) and Welichem Biotech Inc., a company incorporated under the laws of British Columbia with offices at Suite 316, 4475 Wayburne Drive, Burnaby, British Columbia, V5G 3L1, Canada (\u201cWelichem\u201d). GSK and Welichem may be referred to herein separately as a \u201cParty\u201d or together as the \u201cParties.\u201d", "id": "lPGh7edMnRh", "source_url": "https://www.sec.gov/Archives/edgar/data/1753483/000119312519157086/d625659dex1031.htm", "category_name": "Asset Purchase Agreement", "company_name": "Dermavant Sciences LTD", "created": "May 24th, 2019", "published": true, "pretty": null, "uri": "/contracts/lPGh7edMnRh", "title": "ASSET PURCHASE AGREEMENT", "group_id": "lPGh7edMnRh", "group_samples": [{"label": "Asset Purchase Agreement (Dermavant Sciences LTD)", "uri": "/contracts/lPGh7edMnRh", "published": true}], "group_size": 1, "tags": [{"name": "Asset Purchase Agreement", "type": "category", "uri": "/contracts/tagged/asset-purchase-agreement"}, {"name": "Dermavant Sciences LTD", "type": "company", "uri": "/company/1753483/dermavant-sciences-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}], "next_curs": "", "cursor": "CjEKEAoKZ3JvdXBfc2l6ZRICCAEKGQoIZ3JvdXBfaWQSDRoLZGFKb1FodlVQM3AYACAB"}}